Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1998;12(1):20-5.
doi: 10.1002/(sici)1098-2825(1998)12:1<20::aid-jcla4>3.0.co;2-n.

Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients

J T Wu  1 , M E Astill, G H Liu, R A Stephenson
Affiliations

Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients

J T Wu et al. J Clin Lab Anal. 1998.

Abstract

We monitored both chromogranin A (CgA) and neuron specific enolase (NSE) in serial serum specimens from 14 patients with prostate cancer (CAP patients) showing resistance to hormonal treatment. Elevated serum CgA was detected in 10 out of these 14 patients (71%) during treatment, and an early appearance of elevated serum CgA was found in 6 of 14 (43%) of these patients when serum tPSA levels were still in the normal range. If patients with radical prostatectomy were not included, the percentage of patients showing an early appearance of elevated serum CgA would have been much higher. Elevated serum CgA levels also were found in patients not subject to hormonal therapy. Serial specimens from two out of three prostate cancer patients, randomly selected, contained elevated serum CgA. Serum NSE was not detectable in any of the serial specimens we studied, suggesting that CgA, not NSE, should be used as a marker for neuroendocrine differentiation. We also compared the serum CgA in random serum specimens between patients with BPH (benign prostate hyperplasia) and with prostate cancer in the concentration range of serum tPSA between 3-15 ng/mL. Although serum CgA concentrations in BPH patients overlapped considerably with those levels in patients with prostate cancer, levels > 100 ng/mL should suggest prostate cancer. The early appearance of elevated serum CgA allows an early change of therapy to be made and can lead to the effective prevention of any further development of metastases.

PubMed Disclaimer

References

    1. di Sant'Agnese PA, Cockett ATK: Neuroendocrine differentiation in prostatic malignancy. Cancer 78: 357–361, 1996. - PubMed
    1. Tetu B, Ro JY, Ayala AF, Johnson DE, Logothetis CJ, Ordonez NG: Small cell carcinoma of the prostate: Part I. A clinicopathologic study of 20 cases. Cancer 59: 1803, 1987. - PubMed
    1. di Sant'Agnese PA, Cockett ATK: The prostatic endocrine‐paracrine (Neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: A review and future directions in basic research. J Urol 152: 1927–1937, 1994. - PubMed
    1. di Sant'Agnese PA: Neuroendocrine differentiation in prostatic carcinoma. Recent findings and new concepts. Cancer 75: 1850–1859, 1995.
    1. Cussenot O, Villette JM, Valeri A, Cariou G, Descrandschamps F, Cortesse A, Meria P, Teillac P, Fiet J, Le Due A: Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 155: 1340–1343, 1966. - PubMed